RNAi mediated IL-6 in vitro knockdown in psoriasis skin model with topical siRNA delivery system based on liquid crystalline phase

Autor(es)

Depieri, Livia Vieira ; Borgheti-Cardoso, Livia Neves ; Campos, Patricia Mazureki ; Otaguiri, Katia Kaori ; Moura de Carvalho Vicentini, Fabiana Testa ; Lopes, Luciana Biagini ; Vieira Fonseca, Maria Jose ; Vitoria Lopes Badra Bentley, M.

• Tipo de documento: Artigo Científico
• Fonte: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS; v. 105, p. 50-58, AUG 2016.
• Citações Web of Science: 15

Resumo

Gene therapy by RNA interference (RNAi) is a post-transcriptional silencing process that can suppress the expression of a particular gene and it is a promising therapeutic approach for the treatment of many severe diseases, including cutaneous disorders. However, difficulties related to administration and body distribution limit the clinical use of small interfering RNA (siRNA) molecules. In this study, we proposed to use nanocarriers to enable siRNA application in the topical treatment of skin disorders. A siRNA nanodispersion based on liquid crystalline phase and composed of monoolein (MO), oleic acid (OA) and polyethylenimine (PEI) was developed and its physicochemical properties, efficiency of complexation and carrieris/RNA stability were assessed. Subsequently, cell viability, cellular uptake, in vitro skin irritation test using reconstructed human epidermis (RHE) and in vitro IL-6 knockdown in psoriasis skin model were evaluated. The results showed that the liquid crystalline nanodispersion is a promising topical delivery system for administration of siRNA, being able to overcome the limitations of the route of administration, as well those resulting from the characteristics of siRNA molecules. The formulation was effective at complexing the siRNA, presented high rate of cell uptake (similar to 90%), increased the skin penetration of siRNA in vitro, and did not cause skin irritation compared with Triton-X (a moderate irritant), resulting in a 4-fold higher viability of reconstructed human epidermis and a 15.6-fold lower release of IL-1 alpha. A single treatment with the liquid crystalline nanodispersion carrying IL-6 siRNA for 6 h was able to reduce the extracellular IL-6 levels by 3.3-fold compared with control treatment in psoriasis skin model. Therefore, liquid crystalline nanodispersion is a suitable nanocarrier for siRNA with therapeutic potential to suppress skin disease-specific genes. This study also highlights the applicability of reconstructed skin models in pharmaceutical field to evaluate the performance of delivery systems without the use of animal models. (C) 2016 Elsevier B.V. All rights reserved. (AU)

• Processo FAPESP: 04/09465-7 - Laboratório multiusuário de caracterização de sistemas de liberação micro - e nanodispersos de fármacos
• Beneficiário: Maria Vitória Lopes Badra Bentley
• Modalidade de apoio: Auxílio à Pesquisa - Programa Equipamentos Multiusuários
• Processo FAPESP: 12/09125-8 - Nanodispersões de fase líquido cristalina como carreadoras de siRNA no tratamento tópico da psoríase: Avaliação in vitro e in vivo e elucidação dos mecanismos de uptake celular
• Beneficiário: Lívia Vieira Depieri
• Modalidade de apoio: Bolsas no Brasil - Doutorado